CN1273189C - 西尼罗河疫苗 - Google Patents

西尼罗河疫苗 Download PDF

Info

Publication number
CN1273189C
CN1273189C CNB028146646A CN02814664A CN1273189C CN 1273189 C CN1273189 C CN 1273189C CN B028146646 A CNB028146646 A CN B028146646A CN 02814664 A CN02814664 A CN 02814664A CN 1273189 C CN1273189 C CN 1273189C
Authority
CN
China
Prior art keywords
virus
west nile
vaccine
vol
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028146646A
Other languages
English (en)
Chinese (zh)
Other versions
CN1535157A (zh
Inventor
朱贤主
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1535157A publication Critical patent/CN1535157A/zh
Application granted granted Critical
Publication of CN1273189C publication Critical patent/CN1273189C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CNB028146646A 2001-07-27 2002-07-23 西尼罗河疫苗 Expired - Lifetime CN1273189C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
US60/308,334 2001-07-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2006101058113A Division CN1935258B (zh) 2001-07-27 2002-07-23 西尼罗河疫苗

Publications (2)

Publication Number Publication Date
CN1535157A CN1535157A (zh) 2004-10-06
CN1273189C true CN1273189C (zh) 2006-09-06

Family

ID=27613166

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB028146646A Expired - Lifetime CN1273189C (zh) 2001-07-27 2002-07-23 西尼罗河疫苗
CN2006101058113A Expired - Lifetime CN1935258B (zh) 2001-07-27 2002-07-23 西尼罗河疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006101058113A Expired - Lifetime CN1935258B (zh) 2001-07-27 2002-07-23 西尼罗河疫苗

Country Status (24)

Country Link
US (8) US7153513B2 (en:Method)
EP (3) EP2283858A3 (en:Method)
JP (2) JP4718778B2 (en:Method)
KR (2) KR20040028952A (en:Method)
CN (2) CN1273189C (en:Method)
AU (1) AU2002365244B2 (en:Method)
BE (1) BE2014C006I2 (en:Method)
BR (1) BRPI0211492B1 (en:Method)
CA (1) CA2452545C (en:Method)
CY (1) CY2014010I2 (en:Method)
DK (1) DK1427444T3 (en:Method)
ES (1) ES2435095T3 (en:Method)
FR (1) FR14C0016I2 (en:Method)
HR (1) HRP20040195B1 (en:Method)
HU (2) HU228690B1 (en:Method)
LU (1) LU92348I2 (en:Method)
ME (1) ME00491B (en:Method)
MX (1) MXPA04000680A (en:Method)
NZ (3) NZ570270A (en:Method)
PL (2) PL212212B1 (en:Method)
PT (1) PT1427444E (en:Method)
RS (1) RS53184B (en:Method)
WO (1) WO2003061555A2 (en:Method)
ZA (1) ZA200401596B (en:Method)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
EP1664786B1 (en) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2006029300A2 (en) 2004-09-09 2006-03-16 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
RU2436591C2 (ru) * 2005-06-24 2011-12-20 Интервет Интернэшнл Б.В. Инактивированные химерные вакцины и связанные с ними способы применения
NO346351B1 (no) * 2005-10-19 2022-06-20 Intervet Int Bv Isolert hundedyr influensa Avirus, polynukleotid-ekspresjonskonstruksjon, isolert antistoff, isolert celle, reassortant virus og rekombinant virusvektor, samt sammensetning og hundeinfluensavaksine
WO2007047728A2 (en) * 2005-10-20 2007-04-26 Wyeth Compositions and methods for the treatment of canine influenza virus disease
AU2006338210A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
EP2395018B1 (en) * 2006-06-06 2016-01-27 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
CA2725329C (en) 2008-05-23 2013-10-01 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found EQUINE DISEASE MODEL FOR NEUROLOGICAL AUROPTIC VIRUS DISEASE AND USED ASSAYS
WO2010025469A1 (en) * 2008-08-29 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. West nile virus vaccine
BR112012008185A2 (pt) * 2009-10-07 2016-08-16 Wyeth Llc composições que compreendem adjuvante, macrolídeo e antígeno proteináceo, e métodos para uso dessas composições
MX385188B (es) 2011-03-14 2025-03-14 Boehringer Ingelheim Vetmedica Inc Vacuna de rinitis equina.
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
EP3542819B1 (en) * 2013-05-14 2021-08-18 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
HK1224177A1 (zh) * 2013-09-05 2017-08-18 硕腾服务有限责任公司 Hendra和nipah病毒g糖蛋白免疫原性組合物
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
CN113905759A (zh) 2019-02-27 2022-01-07 罗切斯特大学 用于预防和控制马的马流感病毒(eiv)的多价减毒活流感疫苗

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
ATE365049T1 (de) * 1994-05-10 2007-07-15 Wyeth Corp Abgeänderter, verbesserter brsv lebend- impfstoff
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
WO1999063095A1 (en) 1998-06-04 1999-12-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nucleic acid vaccines for prevention of flavivirus infection
US6733994B2 (en) 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
WO2002083903A2 (en) 2001-02-28 2002-10-24 Brown University Research Foundation West nile virus epitopes and uses thereof
EP1372711A4 (en) * 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
HU228690B1 (en) * 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
WO2004016586A2 (en) 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens

Also Published As

Publication number Publication date
JP2011057692A (ja) 2011-03-24
JP4718778B2 (ja) 2011-07-06
BRPI0211492B1 (pt) 2016-06-21
US20070231349A1 (en) 2007-10-04
ES2435095T3 (es) 2013-12-18
HUP0401606A3 (en) 2005-02-28
HU228690B1 (en) 2013-05-28
CN1935258A (zh) 2007-03-28
WO2003061555A2 (en) 2003-07-31
CA2452545A1 (en) 2003-07-31
US20070166325A1 (en) 2007-07-19
HUP0401606A2 (hu) 2004-11-29
US20070178119A1 (en) 2007-08-02
JP2005515236A (ja) 2005-05-26
PL368535A1 (en) 2005-04-04
BE2014C006I2 (en:Method) 2021-02-04
US7445787B2 (en) 2008-11-04
LU92348I2 (fr) 2014-09-22
PL212212B1 (pl) 2012-08-31
KR20040028952A (ko) 2004-04-03
EP2281572A1 (en) 2011-02-09
CY2014010I1 (el) 2020-05-29
KR20090053967A (ko) 2009-05-28
HUS1300055I1 (hu) 2016-08-29
NZ531265A (en) 2008-08-29
AU2002365244B2 (en) 2007-12-06
FR14C0016I2 (fr) 2015-07-24
US20070231350A1 (en) 2007-10-04
US7153513B2 (en) 2006-12-26
US7648705B2 (en) 2010-01-19
US20070166324A1 (en) 2007-07-19
CY2014010I2 (el) 2024-02-16
HRP20040195B1 (hr) 2014-07-18
PL398575A1 (pl) 2012-06-18
BR0211492A (pt) 2004-08-17
EP2283858A3 (en) 2011-03-23
CN1935258B (zh) 2013-04-03
DK1427444T3 (da) 2013-11-04
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
HK1066470A1 (en) 2005-03-24
CA2452545C (en) 2015-06-09
EP2283858A2 (en) 2011-02-16
NZ553165A (en) 2008-09-26
HRP20040195A2 (en) 2004-08-31
EP1427444A4 (en) 2008-01-02
LU92348I9 (en:Method) 2019-01-02
ME00491B (me) 2011-10-10
FR14C0016I1 (en:Method) 2014-03-28
NZ570270A (en) 2010-08-27
US7648706B2 (en) 2010-01-19
MXPA04000680A (es) 2004-04-05
YU8004A (sh) 2006-08-17
RS53184B (en) 2014-06-30
US20070166326A1 (en) 2007-07-19
PL220846B1 (pl) 2016-01-29
US20030091595A1 (en) 2003-05-15
CN1535157A (zh) 2004-10-06
WO2003061555A3 (en) 2004-04-15
US20070166802A1 (en) 2007-07-19
PT1427444E (pt) 2013-11-19
ZA200401596B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
CN1273189C (zh) 西尼罗河疫苗
CN106267195B (zh) 一种猪病毒性腹泻三联抗原抗体复合物及其制备方法
CN1852735A (zh) 包含水包油乳液的疫苗制剂
RU2595873C2 (ru) Вакцинные композиции, содержащие вирус бычьей вирусной диареи 1в типа, и способы их получения и применения
AU2002365244A1 (en) West nile vaccine
CN108220248B (zh) 猪轮状病毒毒株、疫苗组合物及其制备方法和应用
CN111808826B (zh) 猪A型塞内卡病毒SVA/CH-Fuj株及其应用
CN1940063A (zh) 一种伪狂犬病gEˉ/gIˉ基因缺失毒株、含有该毒株的灭活疫苗及应用
CN104258389A (zh) 一种疫苗组合物及其制备方法和应用
CN107541501B (zh) 犬细小病毒毒株、疫苗组合物及其应用
CN108018261A (zh) 犬副流感病毒毒株及其应用
CN109010818A (zh) 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
CN112921006B (zh) 一株鹅星状病毒及其应用
RU2844160C1 (ru) Применение амфифильной высокополимерной дрожжевой РНК в качестве адъюванта при вакцинации
RU2768749C1 (ru) Средство специфической профилактики covid-19 для плотоядных животных
RU2827386C1 (ru) Инактивированная вакцина против ортореовируса рыб
Elgendy et al. Comparative Evaluation of Three Formulae of Bovine Ephemeral Fever Virus Vaccines
RU2449013C2 (ru) Штамм "nadl-вниизж" вируса вирусной диареи крупного рогатого скота diarrhea virus bovinum для изготовления биопрепаратов для диагностики, специфической профилактики и лечения вирусной диареи крупного рогатого скота
Rizk et al. Enhancing effects of Calcium phosphate nanoparticles adjuvant on the Immune response in calves vaccinated with Foot and Mouth Disease trivalent vaccine
Abdel-Samad et al. Validation of Lyophilized-Attenuated Single and Combined Canine Hepatitis, Canine Distemper, and Canine Parvovirus Vaccines
Habel Advances in rabies research
RU2283136C2 (ru) Инактивированная сорбированная вакцина против инфекционной бурсальной болезни птиц
Bhat et al. Enhanced Immune Responses and Protection Against Viral Challenge in Sheep with a Novel Nanoemulsion-Based Inactivated Bluetongue Virus Vaccine
CN119633106A (zh) 用于黏膜免疫的非洲猪瘟病毒灭活疫苗及其制备方法和应用
CN119656297A (zh) 猫泛白细胞减少症、杯状病毒病、鼻气管炎三联灭活疫苗及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: PAHE CO., LTD.

Free format text: FORMER OWNER: WYETH LLC

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: WYETH LLC

Free format text: FORMER NAME: WYETH CORP.

Owner name: SOTEN W CO., LTD.

Free format text: FORMER NAME: PAHE CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: New jersey, USA

Patentee after: WYETH LLC

Address before: New jersey, USA

Patentee before: WYETH

CP03 Change of name, title or address

Address after: New jersey, USA

Patentee after: Zoetis Services LLC

Address before: American New York

Patentee before: Pach LLC

TR01 Transfer of patent right

Effective date of registration: 20130618

Address after: American New York

Patentee after: Pach LLC

Address before: New jersey, USA

Patentee before: Wyeth LLC

ASS Succession or assignment of patent right

Owner name: SHUOTENG SERVICE LLC

Free format text: FORMER OWNER: SOTEN W CO., LTD.

Effective date: 20150807

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150807

Address after: New jersey, USA

Patentee after: Zoetis Services LLC

Address before: New jersey, USA

Patentee before: Zoetis Services LLC

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20060906